CSF3 and breast carcinoma: In 2014, a long-acting granulocyte-colony stimulating factor (G-CSF) was approved for breast cancer by the national health insurance in Japan after which it has increasingly been administered to prevent febrile neutropenia (FN) without hospitalization.